As a very rare side effect, AstraZeneca may cause a defensive reaction in the body, says Asko Järvinen, Hus’s chief physician. The causal link is not yet certain, and in any case the risk is so small that Järvinen himself would take the vaccine.
Helsinki and the Chief Physician of the Uusimaa Hospital District (Hus) Asko Järvisen According to AstraZeneca, the link between the coronary vaccine and the superficial vein thrombosis is still unclear.
There have been a few dozen suspected cases around the world. Almost 200,000 doses of AstraZeneca have been given in Finland. There have been 2–3 cases in Finland where the connection of AstraZeneca to cerebral venous thrombosis has been investigated.
– There is no clear case definition, but they are so similar that it seems to me that some kind of connection with the vaccine is likely, Järvinen says.
Read more: WHO: Astra Zeneca does not appear to increase blood clots – benefits outweigh disadvantages
Järvinen AstraZeneca says that in the light of current data, the AstraZeneca vaccine may, as a very rare side effect, trigger a defense response against platelets in the body.
In this case, the number of platelets first increases, and then they go very low. In the initial stage, a blood clot forms.
– The risk is not of the type that would increase the incidence of ordinary blood clots, Järvinen says.
– For some reason, this type of mechanism would seem to lead to a blood clot in the superficial vein (sinus sagittalis) of the brain.
In the past, two independent research groups have come to a similar conclusion about the mechanism.
Read more: Two groups of researchers found a possible link between AstraZeneca vaccine and cerebral venous thrombosis
The symptoms of a blood clot like this are pretty vague. Symptoms include prolonged headache, and may include visual disturbances and dizziness, i.e., symptoms of the central nervous system.
– According to current information, the symptoms come 4 to 14 days after the first vaccination, Järvinen says.
The European Medicines Agency (EMA) said on Friday last week that those who received AstraZeneca had blood clotting problems and cerebral venous thrombosis, mainly in women under 55 years of age.
Aivon the superficial-vein blood clot is poorly visible on a standard head computer scan. Its detection requires magnetic resonance imaging or head imaging with enhanced venous structure.
According to Järvinen, a blood clot in the surface vein of the brain is not terribly dangerous in itself, and it can be treated with blood thinning.
– But the problem is that there is a risk of bleeding in that condition. In other words, there may be bleeding after the plug, so the plug must be treated with great care, Järvinen says.
– This condition can be easily identified from the hematopoiesis by platelet deficiency, and then by defining D-dimer or FiDD blood clotting products.
It is not yet known whether a person may have any risk factors for this type of blood clot.
– Apparently, those who have had a blood clot, a risk of blood clots, or blood thinning treatment are not at a higher risk. This is a completely different mechanism.
Järvinen was the first to talk about the topic at Yle’s Ykkösaamu.
In the program, Järvinen also said that he would take the AstraZeneca vaccine himself, as Järvinen, who will soon be 60 years old, considers covid-19 to be a greater threat than the vaccine.
– At this age (the risk of a serious disease) is greater than the risk of a vaccine, Järvinen said in Yle.
The Department of Health and Welfare (THL) decided on Wednesday that vaccinations with the AstraZeneca vaccine will continue in Finland for people over 65 years of age.
Read more: Finland continues to use AstraZeneca’s Korona vaccine – Fime is not considered a health risk
Source site www.is.fi